The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Co. Awaits FDA Approval of Drug, Prepares for Launch

Research Report
  ()
The biopharma's executive team is managing both time and opex spending well, noted an Oppenheimer report.

Drug Co. Gets PDUFA Date for TKI

Research Report
  ()
"We expect poziotinib approval in late 2022 with sales of $21.9 million this year," noted an H.C. Wainwright & Co. report.

Catalyst Could Push Pharma to Break Out

Contributed Opinion
  ()
This pharmaceutical company is trading well below its cash value and is on the cusp of a potentially significant catalyst, one analyst says.

Biotech Firm Should Increase Sales by 20% This Year

Research Report
  ()
This immunotherapy company's outlook for 2022 is positive with expected growth in overall product sales and progress on the clinical front, noted an H.C. Wainwright & Co. report.

Co.'s Catalyst Rich 2022 Includes NDA, MAA Filings

Research Report
  ()
An Oppenheimer report notes that this pharmaceutical company is working to expand the approved uses of its lead drug candidate, and numerous catalysts involving Empaveli are expected this year.

This Year Should Be Catalyst Rich for Oncology Pharma Co.

Research Report
  ()
An outperform-rated biopharma, which has a robust year of significant events ahead, is trading now at a significant discount, noted a Wedbush report.

Biotech to Take Novel Cancer Drug to Market in H1/22

  ()
This biotech company is commercializing its lead drug candidate, Kimmtrak, has a catalyst-rich 2022, and has various clinical-stage drugs for cancers and autoimmune and infectious diseases.

Super Computers Create Powerful Drugs for Alzheimer's

  ()
A promising biotech company is finding new ways to treat neurodegenerative diseases by focusing on misfolded proteins.

Canadian Hedge Fund CIO Talks Top 2022 Prospects

  ()
AlphaNorth Asset Management was recently recognized as the Number One equity hedge fund in Canada at the 2021 Alternative IQ Canadian Hedge Fund Awards due to its 5-year average investment return of 40.35%. Streetwise Reports sat down with the firm's co-Founder Steven Palmer to discuss some of the firm's recent investments and emerging opportunities for 2022.

Todos COVID-19 Drug Shows Superiority to Remdesivir, Takes Dying Off the Table

Contributed Opinion
  ()
In a phase 2 clinical study, Todos Medical's oral antiviral Tollovir showed a 100% reduction in mortality from COVID-19.

Investors: Will a Psychedelic Drug Take This Pharma Stock to the Next Level?

  ()
Algernon Pharmaceuticals plans to be the world's first company to test the psychedelic drug DMT in stroke patients, and it's close to achieving its goal.

Drug Re-Purposing Co. Pursues Novel Stroke Therapies

  ()
Drug re-purposing co. Algernon Pharmaceuticals Inc. is actively reinventing itself. The firm's leading therapeutic candidate NP-120 (Ifenprodil) is currently being evaluated in a Phase 2 trial for IPF and chronic cough, and the company is now moving forward with a revolutionary new use for DMT to treat ischemic stroke.

Co. Focused on Pipeline of Drug Candidates

Research Report
  ()
In the clinic, Algernon Pharmaceuticals is advancing Ifenprodil in three indications and DMT in stroke, noted a Research Capital Corp. report.

Showing Results: 26 to 50 of 105 Prev Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts